Hemostatic Disturbances in Uremic Syndrome: The Role of Platelet Dysfunction and Uremic Toxins — A Literature Review
DOI:
10.29303/jbt.v26i4a.13865Published:
2026-11-15Downloads
Abstract
Uremic syndrome develops in advanced kidney dysfunction as retained solutes and metabolic disturbances affect multiple organ systems. Hemostatic abnormalities in this condition are complex because patients may experience both bleeding and thrombotic complications. This review aimed to describe the pathophysiological mechanisms underlying hemostatic disturbances in uremic syndrome, with particular emphasis on platelet dysfunction, uremic toxins, and endothelial alterations. A narrative literature review was conducted using relevant research articles, review articles, systematic reviews, meta-analyses, and textbooks discussing hemostasis in chronic kidney disease and uremia. The reviewed evidence indicates that alterations in platelet adhesion, activation, granule secretion, and aggregation may impair primary hemostasis. However, platelet activity is not consistently reduced. Protein-bound uremic toxins, particularly indoxyl sulfate, may contribute to oxidative stress and enhance platelet reactivity in experimental models. Other findings demonstrate reduced secondary platelet responses in patients with advanced chronic kidney disease, suggesting that platelet dysfunction involves more than one mechanism. Uremic toxins may also contribute to endothelial dysfunction and inflammatory responses, further disturbing vascular homeostasis. In addition, anemia, dialysis-related factors, comorbidities, and antithrombotic treatment may influence the hemostatic balance. These findings indicate that hemostatic abnormalities in uremic syndrome arise from complex interactions among platelets, the vascular endothelium, and systemic factors. Understanding these mechanisms is important for assessing bleeding and thrombotic risks in patients with advanced kidney disease.
Keywords:
Chronic kidney disease Hemostasis Platelet dysfunction Uremic syndrome Uremic toxinsReferences
Baaten, C. C. F. M. J., Sternkopf, M., Henning, T., Marx, N., Jankowski, J., & Noels, H. (2021). Platelet function in CKD: A systematic review and meta-analysis. Journal of the American Society of Nephrology, 32(7), 1583–1598. https://doi.org/10.1681/ASN.2020101440
Baaten, C. C. F. M. J., Wollenhaupt, J., Henning, T. M., Vondenhoff, S., Schröer, J. R., Stamellou, E., et al. (2025). Impaired secondary platelet response in chronic kidney disease as a consequence of prior platelet activation. JACC: Basic to Translational Science, 10(9), Article 101355. https://doi.org/10.1016/j.jacbts.2025.101355
Cho, M. E., Brunt, V. E., Shiu, Y.-T., & Bunsawat, K. (2025). Endothelial dysfunction in chronic kidney disease: A clinical perspective. American Journal of Physiology-Heart and Circulatory Physiology, 329(1), H135–H153. https://doi.org/10.1152/ajpheart.00908.2024
da Cunha, R. S., Santos, A. F., Barreto, F. C., & Stinghen, A. E. M. (2020). How do uremic toxins affect the endothelium? Toxins, 12(6), Article 412. ttps://doi.org/10.3390/toxins12060412
Daugirdas, J. T., & Bernardo, A. A. (2012). Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia. Kidney International, 82(2), 147–157. https://doi.org/10.1038/ki.2012.130
Harlacher, E., Wollenhaupt, J., Baaten, C. C. F. M. J., & Noels, H. (2022). Impact of uremic toxins on endothelial dysfunction in chronic kidney disease: A systematic review. International Journal of Molecular Sciences, 23(1), Article 531. https://doi.org/10.3390/ijms23010531
Hedges, S. J., Dehoney, S. B., Hooper, J. S., Amanzadeh, J., & Busti, A. J. (2007). Evidence-based treatment recommendations for uremic bleeding. Nature Clinical Practice Nephrology, 3, 138–153. https://doi.org/10.1038/ncpneph0421
Jain, N., Corken, A. L., Kumar, A., Davis, C. L., Ware, J., & Arthur, J. M. (2021). Role of platelets in chronic kidney disease. Journal of the American Society of Nephrology, 32(7), 1551–1558. https://doi.org/10.1681/ASN.2020121806
Jin, R. C., Voetsch, B., & Loscalzo, J. (2005). Endogenous mechanisms of inhibition of platelet function. Microcirculation, 12(3), 247–258. https://doi.org/10.1080/10739680590925493
Lutz, J., & Jurk, K. (2020). Platelets in advanced chronic kidney disease: Two sides of the coin. Seminars in Thrombosis and Hemostasis, 46(3), 342–356. https://doi.org/10.1055/s-0040-1708841
Mihai, S., Codrici, E., Popescu, I. D., Enciu, A. M., Rusu, E., Zilisteanu, D., et al. (2018). Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. Journal of Immunology Research, 2018, Article 2180373. https://doi.org/10.1155/2018/2180373
Mohapatra, A., Valson, A. T., Gopal, B., Singh, S., Nair, S. C., Viswabandya, A., et al. (2018). Hemostatic abnormalities in severe renal failure: Do they bark or bite? Indian Journal of Nephrology, 28(2), 135–142. https://doi.org/10.4103/ijn.IJN_104_17
Neubauer, K., & Zieger, B. (2022). Endothelial cells and coagulation. Cell and Tissue Research, 387, 391–398. https://doi.org/10.1007/s00441-021-03471-2
Parul, F., Ratnani, T., Subramani, S., Bhatia, H., Ashmawy, R. E., Nair, N., et al. (2025). Anticoagulation in patients with end-stage renal disease: A critical review. Healthcare, 13(12), Article 1373. https://doi.org/10.3390/healthcare13121373
Periayah, M. H., Halim, A. S., & Mat Saad, A. Z. (2017). Mechanism action of platelets and crucial blood coagulation pathways in hemostasis. International Journal of Hematology-Oncology and Stem Cell Research, 11(4), 319–327.
Qiu, Z., Pang, X., Xiang, Q., & Cui, Y. (2023). The crosstalk between nephropathy and coagulation disorder: Pathogenesis, treatment, and dilemmas. Journal of the American Society of Nephrology, 34(11), 1793–1811. https://doi.org/10.1681/ASN.0000000000000199
Rosner, M. H., Reis, T., Husain-Syed, F., Vanholder, R., Hutchison, C., Stenvinkel, P., et al. (2021). Classification of uremic toxins and their role in kidney failure. Clinical Journal of the American Society of Nephrology, 16(12), 1918–1928. https://doi.org/10.2215/CJN.02660221
Weigert, A. L., & Schafer, A. I. (1998). Uremic bleeding: Pathogenesis and therapy. The American Journal of the Medical Sciences, 316(2), 94–104.
Yang, K., Du, C., Wang, X., Li, F., Xu, Y., Wang, S., et al. (2017). Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease-associated thrombosis in mice. Blood, 129(19), 2667–2679. https://doi.org/10.1182/blood-2016-10-744060
License
Copyright (c) 2026 M. Davi Arya Amri, Balqiis El-Fayyaza Markuadi, Natalia Tantowi, Zulfa Hanna Azizah, Amelia Khairunnisa, Dinda Rahma Ayu, Ida Bagus Nanda Adi Putra, Raffi Aprilian Romeo Putra, Fachrizal Ahmad Haryo Radityo, Nagina Zanur Putri, Rasya Kirania Putri, Joko Anggoro

This work is licensed under a Creative Commons Attribution 4.0 International License.

Jurnal Biologi Tropis is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of the received article shall be assigned to the author as the owner of the paper. The intended copyright includes the right to publish the article in various forms (including reprints). The journal maintains the publishing rights to the published articles.
Authors are permitted to disseminate published articles by sharing the link/DOI of the article at the journal. Authors are allowed to use their articles for any legal purposes deemed necessary without written permission from the journal with an acknowledgment of initial publication to this journal.























